Vascular Biogenics (NASDAQ:VBLT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a report issued on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Zacks Investment Research lowered Vascular Biogenics from a buy rating to a hold rating in a report on Friday, January 7th. One analyst has […]

Related Keywords

,Vascular Biogenics Company Profile Get Rating ,Goldman Sachs Group Inc ,Zacks Investment Research ,Vascular Biogenics Ltd ,Millennium Management ,Spectrum Planning Advisory Services Inc ,Vascular Biogenics ,Get Rating ,Sigma Advisers ,Advisory Services ,Sachs Group ,Street Group ,Biogenics Company Profile ,Nasdaq Vblt ,Vblt ,Medical ,Initiated Coverage ,Stocknews Com ,